Dilated Cardiomyopathy : From Genetics to Clinical Management.
| Main Author: | |
|---|---|
| Other Authors: | , |
| Format: | eBook |
| Language: | English |
| Published: |
Cham :
Springer International Publishing AG,
2019.
|
| Edition: | 1st ed. |
| Subjects: | |
| Online Access: | Click to View |
Table of Contents:
- Intro
- Contents
- Introduction
- 1: Historical Terminology, Classifications, and Present Definition of DCM
- 1.1 Dilated Cardiomyopathies: The Classification Pathway
- 1.2 Genetic Dilated Cardiomyopathy and Etiological Classification
- 1.3 Future Perspectives
- References
- 2: Epidemiology
- 2.1 Towards Contemporary Clinical Epidemiology in Dilated Cardiomyopathy
- 2.2 Genetics and Future Perspectives
- References
- 3: Pathophysiology
- 3.1 Ventricular Remodeling in DCM
- 3.2 Genetic Pathophysiology and New Possible Proteins Involved in DCM [2]
- 3.3 Molecular Mechanisms of Cardiac Remodeling in HF [15]
- References
- 4: Etiological Definition and Diagnostic Work-Up
- 4.1 Clinical Presentation
- 4.2 Etiological Classification: A Critical Issue in Clinical Management of DCM
- 4.2.1 Need of Reclassification of the Disease During Follow-Up
- 4.3 Exclusion of Reversible Causes of Left Ventricular Dysfunction/Dilation
- 4.4 Diagnostic Work-Up in New-Onset LV Dysfunction/Dilation: A "Red Flags" Approach
- 4.4.1 Personal and Family History
- 4.4.2 Symptoms and Physical Examination
- 4.4.3 12 Lead Electrocardiogram
- 4.4.4 Laboratory Tests
- 4.4.4.1 Genetic Testing
- 4.4.5 Echocardiography
- 4.4.6 Cardiovascular Magnetic Resonance
- 4.4.7 Cardiac Catheterizations and Procedures
- 4.4.7.1 Coronary Angiogram
- 4.4.7.2 Cardiac Catheterization
- 4.4.7.3 Endomyocardial Biopsy
- 4.5 Conclusions
- References
- 5: Genetics of Dilated Cardiomyopathy: Current Knowledge and Future Perspectives
- 5.1 DCM-Associated Genes
- 5.1.1 Titin
- 5.1.2 Lamin A/C
- 5.1.3 Structural Cytoskeleton Z-Disk Genes
- 5.1.4 Desmosomal Genes
- 5.1.5 Sarcomeric (Motor) Genes
- 5.1.6 Ion Channel-Related Genes
- 5.1.7 Other Genes
- 5.2 Technical Issues in Genetic Sequencing.
- 5.3 The Complexity in Variant Classification Process
- 5.4 The External Modulation of Genotype: Environmental Triggers
- 5.5 Evidence-Based Genotype-Phenotype Correlations
- 5.5.1 Lamin A/C
- 5.5.2 Titin
- 5.5.3 Filamin C
- 5.5.4 Insights from Clinical Presentation and Left Ventricular Reverse Remodeling (LVRR)
- References
- 6: Clinical Presentation, Spectrum of Disease, and Natural History
- 6.1 Spectrum of Disease
- 6.2 Clinical Presentation
- 6.3 Natural History
- References
- 7: Role of Cardiac Imaging: Echocardiography
- 7.1 Echocardiographic Features of Dilated Cardiomyopathy
- 7.2 Role of New Echocardiographic Techniques
- 7.3 Clinical Echocardiography in DCM: Advantages and Limitations in Clinical Practice
- 7.4 Prognostic Role of Echocardiographic Data in DCM
- References
- 8: Role of Cardiac Imaging: Cardiac Magnetic Resonance and Cardiac Computed Tomography
- 8.1 Cardiac Magnetic Resonance
- 8.2 Diagnostic Accuracy
- 8.3 Differential Diagnosis
- 8.4 Myocarditis Presenting as Left Ventricular Dysfunction
- 8.5 Other Secondary Forms of DCM
- 8.6 Prognostic Stratification
- 8.7 Macroscopic vs. Diffuse Fibrosis
- 8.8 Strain Analysis
- 8.9 Other Prognostic Indicators
- 8.10 Computed Tomography
- References
- 9: Endomyocardial Biopsy
- 9.1 Introduction
- 9.2 Technique
- 9.3 Complications
- 9.4 Indications in DCM Scenarios
- 9.5 Diagnosis of Myocarditis
- 9.6 Examples of Endomyocardial Biopsy
- 9.6.1 Case I (J.D.)
- 9.6.2 Case II (C.P.)
- 9.6.3 Case III (C.S.)
- 9.6.4 Case IV (C.F.)
- References
- 10: Arrhythmias in Dilated Cardiomyopathy: Diagnosis and Treatment
- 10.1 Burden and Kinds of Arrhythmias in Dilated Cardiomyopathy: Risk Stratification of Sudden Death
- 10.1.1 Bradyrhythmias and Conduction Abnormalities
- 10.1.2 Supraventricular Arrhythmias.
- 10.1.3 Ventricular Arrhythmias
- 10.1.4 Mechanisms
- 10.1.5 Risk Stratification of Sudden Cardiac Death
- 10.1.6 Role of Supraventricular and Ventricular Arrhythmias in Pathogenesis of DCM
- 10.1.6.1 Definition and Pathophysiology
- 10.1.6.2 Specific Clinical Pictures
- 10.1.7 Management of Atrial Arrhythmias in Dilated Cardiomyopathy and Heart Failure
- 10.1.8 Management of Ventricular Arrhythmias in Dilated Cardiomyopathy
- 10.1.9 Antiarrhythmic Drug Therapy of Ventricular Arrhythmias
- 10.1.10 Catheter Ablation of Ventricular Arrhythmias
- 10.1.11 Characteristics of the Arrhythmogenic Substrate and Its Impact on Catheter Ablation Approach
- 10.1.12 Role of ICD in DCM
- References
- 11: Regenerative Medicine and Biomarkers for Dilated Cardiomyopathy
- 11.1 Strategies for Heart Regeneration
- 11.1.1 Cell Therapy
- 11.1.2 Gene Therapy
- 11.2 Regenerative Approaches in Dilated Cardiomyopathy
- 11.3 Biomarkers and Dilated Cardiomyopathy
- References
- 12: Prognostic Stratification and Importance of Follow-Up
- 12.1 Prognosis of DCM: The Milestones of the Management
- 12.2 Etiological Characterization as an Important Prognostic Factor
- 12.3 DCM as a Dynamic Disease: The Importance of Follow-Up
- 12.4 Left Ventricular Reverse Remodeling Beyond the Left Ventricle
- 12.5 Prognostic Role of Cardiopulmonary Exercise Testing
- 12.6 Arrhythmic Risk Stratification
- 12.7 The "Apparent Healing" Phenomenon
- 12.8 Uninterrupted Follow-Up and Continuous Reclassification of the Disease
- References
- 13: Current Management and Treatment
- 13.1 Familial Screening Program
- 13.2 Sport Activity Screening Program
- 13.3 Medical Treatment
- 13.4 Ventricular and Supraventricular Arrhythmias
- 13.5 Implantable Cardioverter-Defibrillator
- 13.6 Cardiac Resynchronization Therapy.
- 13.7 Advanced Heart Failure, Mechanical Circulatory Support, Functional Mitral Regurgitation Correction, Heart Transplantation, and Palliative Care
- References
- 14: Unresolved Issues and Future Perspectives
- 14.1 Toward a Personalized Medicine: A Genetic Approach
- 14.2 The Challenge of Arrhythmic Stratification
- 14.3 Toward Innovation in Therapy
- References
- 15: Dilated Cardiomyopathy at the Crossroad: Multidisciplinary Approach
- 15.1 Sarcoidosis: Co-working with Pneumologists
- 15.1.1 Treatment
- 15.2 Autoimmune Cardiomyopathy: Co-working with Rheumatologists
- 15.2.1 Systemic Lupus Erythematosus
- 15.2.2 Treatment
- 15.3 Infectious Disease and Cardiomyopathy: Co-working with Infectious Disease Specialist
- 15.3.1 Chagas Cardiomyopathy
- 15.3.2 Treatment
- 15.3.3 Lyme Disease
- 15.3.4 Treatment
- 15.4 Dilated Cardiomyopathy Associated with Neuromuscular Diseases: Co-working with Neurologists
- 15.5 Primary Iron-Overload Cardiomyopathy: Co-working with the Hematologists
- 15.6 Cardiomyopathy Related to Chemotherapeutic Agents: Co-working with Oncologists
- 15.6.1 Treatment
- 15.7 Alcoholic Cardiomyopathy
- 15.7.1 Treatment
- References.